Justice Department Issues Subpoenas to Merck Over Drug Marketing
The DOJ is seeking information about the marketing and selling activities for Temodar, PegIntron and IntronA from 2004-present. The drugs were marketed by Schering-Plough for most of that time — a company Merck acquired in 2009.
Temodar sales totaled $481 million for the first six months of 2011. PegIntron generated $319 million and Intron A had $96 million in sales in that time, according to the report.
Merck said it is cooperating with the probe but could not provide further comment.
Read the Wall Street Journal report on Merck.
Related Articles on Pharmaceutical Companies:Massachusetts Files Suit Against Johnson & Johnson Over Risperdal Marketing
Arkansas to Bring AstraZeneca to Trial in 2012 For Alleged Off-Label Marketing
Supreme Court Rejects Appeal to Revive Class-Action Suit Against Eli Lilly
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.